ArticleCancers2011
From prostate to bone: key players in prostate cancer bone metastasis.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Differential Effects of a First-in-Class IKKCalcified tissue international · 2026Article
- Metastatic Prostate Cancer Presenting as Fatigue in an Older Adult.Clinical case reports · 2026Article
- FOXI3 promotes migration and proliferation in prostate cancer bone metastases, modulated by FGF8.Frontiers in oncology · 2026Article
- Low-magnitude high-frequency vibration reduces prostate cancer growth and extravasationMechanobiology in medicine · 2024Article
- Article
- The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.Biomedicines · 2024Review
- Article
- Microfluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer.Cells · 2024Review
- Engineering models of head and neck and oral cancers on-a-chip.Biomicrofluidics · 2024Review
- Osteoclasts directly influence castration-resistant prostate cancer cells.Clinical & experimental metastasis · 2022Article
- What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary.Journal of musculoskeletal & neuronal interactions · 2021Article
- Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.Frontiers in genetics · 2021Review
- Medullary Aplasia Revealing a Metastatic Prostatic Adenocarcinoma.Case reports in urology · 2021Article
- PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.Biochemical pharmacology · 2020Article
- Roles of omental and bone marrow adipocytes in tumor biology.Adipocyte · 2019Review
- Observational
- A case of metastatic prostate cancer and immune thrombocytopenia.Current oncology (Toronto, Ont.) · 2017Article
- Metastatic Prostate Cancer to the Left Temporal Bone: A Case Report and Review of the Literature.Case reports in otolaryngology · 2015Article
- Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.Cancer metastasis reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Bone is the most common site for metastasis in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of prostate cancer patients. Despite advances in our understanding of the biology of primary prostate tumors, our knowledge of how and why secondary tumors derived from prostate cancer cells preferentially localize bone remains limited. The physiochemical properties of bone, and signaling molecules including specific chemokines and their receptors, are distinct in nature and function, yet play intricate and significant roles in prostate cancer bone metastasis. Examining the impact of these facets of bone metastasis in vivo remains a significant challenge, as animal models that mimic the natural history and malignant progression clinical prostate cancer are rare. The goals of this article are to discuss (1) characteristics of bone that most likely render it a favorable environment for prostate tumor cell growth, (2) chemokine signaling that is critical in the recruitment and migration of prostate cancer cells to the bone, and (3) current animal models utilized in studying prostate cancer bone metastasis. Further research is necessary to elucidate the mechanisms underlying the extravasation of disseminated prostate cancer cells into the bone and to provide a better understanding of the basis of cancer cell survival within the bone microenvironment. The development of animal models that recapitulate more closely the human clinical scenario of prostate cancer will greatly benefit the generation of better therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.